Revenue from Contract with Customer, Excluding Assessed Tax of Avid Bioservices, Inc. from 30 Apr 2018 to 31 Oct 2024

Taxonomy & unit
us-gaap: USD
Description
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
Summary
Avid Bioservices, Inc. quarterly and annual Revenue from Contract with Customer, Excluding Assessed Tax in USD history and change rate from 30 Apr 2018 to 31 Oct 2024.
  • Avid Bioservices, Inc. Revenue from Contract with Customer, Excluding Assessed Tax for the quarter ending 31 Oct 2024 was $33,482,000, a 32% increase year-over-year.
  • Avid Bioservices, Inc. Revenue from Contract with Customer, Excluding Assessed Tax for the twelve months ending 31 Oct 2024 was $150,445,000, a 6.7% increase year-over-year.
  • Avid Bioservices, Inc. annual Revenue from Contract with Customer, Excluding Assessed Tax for 2023 was $139,911,000, a 6.3% decline from 2022.
  • Avid Bioservices, Inc. annual Revenue from Contract with Customer, Excluding Assessed Tax for 2022 was $149,266,000, a 25% increase from 2021.
  • Avid Bioservices, Inc. annual Revenue from Contract with Customer, Excluding Assessed Tax for 2021 was $119,597,000, a 25% increase from 2020.
Source SEC data
View on sec.gov
Revenue from Contract with Customer, Excluding Assessed Tax, Trailing 12 Months (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, Quarterly (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, YoY Quarterly Change (%)
Revenue from Contract with Customer, Excluding Assessed Tax, Annual (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, YoY Annual Change (%)

Avid Bioservices, Inc. Quarterly Revenue from Contract with Customer, Excluding Assessed Tax (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2024 $150,445,000 $33,482,000 +$8,087,000 +32% 01 Aug 2024 31 Oct 2024 10-Q 10 Dec 2024 2025 Q2
Q2 2024 $142,358,000 $40,173,000 +$2,447,000 +6.5% 01 May 2024 31 Jul 2024 10-Q 09 Sep 2024 2025 Q1
Q1 2024 $139,911,000 $42,975,000 +$3,176,000 +8% 01 Feb 2024 30 Apr 2024 10-K 02 Jul 2024 2024 FY
Q4 2023 $136,735,000 $33,815,000 -$4,203,000 -11% 01 Nov 2023 31 Jan 2024 10-Q 24 Apr 2024 2024 Q3
Q3 2023 $140,938,000 $25,395,000 -$9,362,000 -27% 01 Aug 2023 31 Oct 2023 10-Q 10 Dec 2024 2025 Q2
Q2 2023 $150,300,000 $37,726,000 +$1,034,000 +2.8% 01 May 2023 31 Jul 2023 10-Q 09 Sep 2024 2025 Q1
Q1 2023 $149,266,000 $39,799,000 +$8,573,000 +27% 01 Feb 2023 30 Apr 2023 10-K 02 Jul 2024 2024 FY
Q4 2022 $140,693,000 $38,018,000 +$6,510,000 +21% 01 Nov 2022 31 Jan 2023 10-Q 24 Apr 2024 2024 Q3
Q3 2022 $134,183,000 $34,757,000 +$8,648,000 +33% 01 Aug 2022 31 Oct 2022 10-Q/A 24 Apr 2024 2024 Q2
Q2 2022 $125,535,000 $36,692,000 +$5,938,000 +19% 01 May 2022 31 Jul 2022 10-Q/A 24 Apr 2024 2024 Q1
Q1 2022 $119,597,000 $31,226,000 +$3,620,000 +13% 01 Feb 2022 30 Apr 2022 10-K 02 Jul 2024 2024 FY
Q4 2021 $115,977,000 $31,508,000 +$9,702,000 +44% 01 Nov 2021 31 Jan 2022 10-Q 13 Mar 2023 2023 Q3
Q3 2021 $106,275,000 $26,109,000 +$5,045,000 +24% 01 Aug 2021 31 Oct 2021 10-Q 06 Dec 2022 2022 Q2
Q2 2021 $101,230,000 $30,754,000 +$5,362,000 +21% 01 May 2021 31 Jul 2021 10-Q 06 Sep 2022 2023 Q1
Q1 2021 $95,868,000 $27,606,000 +$15,056,000 +120% 01 Feb 2021 30 Apr 2021 10-K/A 24 Apr 2024 2023 FY
Q4 2020 $80,812,000 $21,806,000 +$8,221,000 +61% 01 Nov 2020 31 Jan 2021 10-Q 08 Mar 2022 2022 Q3
Q3 2020 $72,591,000 $21,064,000 +$2,751,000 +15% 01 Aug 2020 31 Oct 2020 10-Q 07 Dec 2021 2022 Q2
Q2 2020 $69,840,000 $25,392,000 +$10,138,000 +66% 01 May 2020 31 Jul 2020 10-Q 08 Sep 2021 2021 Q1
Q1 2020 $59,702,000 $12,550,000 01 Feb 2020 30 Apr 2020 10-K 29 Jun 2022 2022 FY
Q4 2019 $13,585,000 01 Nov 2019 31 Jan 2020 10-Q 08 Mar 2021 2021 Q3
Q3 2019 $18,313,000 01 Aug 2019 31 Oct 2019 10-Q 02 Dec 2020 2021 Q2
Q2 2019 $15,254,000 01 May 2019 31 Jul 2019 10-Q 01 Sep 2020 2021 Q1

Avid Bioservices, Inc. Annual Revenue from Contract with Customer, Excluding Assessed Tax (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2023 $139,911,000 -$9,355,000 -6.3% 01 May 2023 30 Apr 2024 10-K 02 Jul 2024 2024 FY
2022 $149,266,000 +$29,669,000 +25% 01 May 2022 30 Apr 2023 10-K 02 Jul 2024 2024 FY
2021 $119,597,000 +$23,729,000 +25% 01 May 2021 30 Apr 2022 10-K 02 Jul 2024 2024 FY
2020 $95,868,000 +$36,166,000 +61% 01 May 2020 30 Apr 2021 10-K/A 24 Apr 2024 2023 FY
2019 $59,702,000 +$6,099,000 +11% 01 May 2019 30 Apr 2020 10-K 29 Jun 2022 2022 FY
2018 $53,603,000 -$18,000 -0.03% 01 May 2018 30 Apr 2019 10-K 29 Jun 2021 2021 FY
2017 $53,621,000 01 May 2017 30 Apr 2018 10-K 30 Jun 2020 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.